Conflombardia – Europa
Territori d’Europa
Tutti gli articoli
www.ema.europa.eu EMA has issued recommendations for the influenza virus strains1,2 that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2026. Every year, EMA issues EU recommendations for the composition of seasonal influenza vaccines...
www.ema.europa.eu The advisory group on vaccine confidence will meet quarterly. It includes academics, representatives of healthcare professionals, medical societies and patient organisations, as well as public health bodies. Its composition and terms of reference are published on EMA’s...
www.ema.europa.eu EMA has launched a pilot programme to support the development of breakthrough medical devices in the European Union (EU). The purpose of the pilot is to test a new regulatory pathway that supports patient access to highly innovative technologies, while maintaining the EU’s...
www.ema.europa.eu Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its April 2026 meeting. The committee recommended granting a marketing authorisation for Cenrifki (tolebrutinib), for the treatment of...
www.ema.europa.eu EMA has recommended granting a marketing authorisation in the European Union (EU) for Redemplo (plozasiran) to treat adults with familial chylomicronaemia syndrome (FCS). FCS is a rare inherited disease that prevents the body from breaking down lipids (fats). People with...
www.ema.europa.eu CVMP opinions on veterinary medicinal products The Committee adopted a positive opinion for a marketing authorisation for Nobivac NXT HCPChFeLV, for the active immunisation of cats to reduce mortality, clinical signs and virus excretion caused by infection with feline...